Cancer patients now wait longer to start treatment than a decade ago, study finds

A new study analysing treatment records across multiple cancer types has found that the interval between diagnosis and the start of treatment has grown substantially longer over the past decade, a trend researchers describe as consistent and troubling. One of the study's authors summarised the finding directly: across every cancer type examined, patients are waiting longer today to begin treatment than they were ten years ago.

The research draws on treatment timing data spanning a ten-year window, comparing how quickly patients moved from initial diagnosis to their first treatment session — whether surgery, chemotherapy, radiation or another intervention — at the start of that period versus the end of it. Across nearly every cancer type in the dataset, the researchers found the same directional trend: longer waits now than then.

Timing matters significantly in cancer care because many tumours continue to grow and, in some cases, spread during the interval between diagnosis and treatment. Multiple prior studies have linked longer diagnosis-to-treatment intervals with worse outcomes for several cancer types, giving clinical weight to what might otherwise read as a purely administrative or logistical finding.

The study does not point to a single explanation for the lengthening delays, but researchers and clinicians point to several plausible contributing factors converging over the same period: growing complexity in diagnostic workups, including more extensive imaging and biomarker testing before a treatment plan is finalised; persistent workforce shortages among oncologists, radiologists and specialised support staff; and rising overall demand for cancer care as populations age and detection improves.

Healthcare system capacity constraints are a recurring theme in how researchers and clinicians interpret the trend. Even when a cancer diagnosis is confirmed quickly, the subsequent steps — staging scans, multidisciplinary treatment-planning meetings, scheduling surgery or securing an appointment with a specialist — each depend on system capacity that has not necessarily scaled alongside patient volume.

The study's authors caution against interpreting the trend as evidence that cancer care itself has become less effective; treatment options and survival rates for many cancers have continued to improve over the same decade. Rather, they frame the finding as evidence of a system under increasing strain in the specific window between diagnosis and treatment initiation, a phase that has received comparatively less research and policy attention than treatment efficacy itself.

Patient experience during this waiting period is an area the study's authors flag as needing more attention. Beyond the clinical stakes of delayed treatment, patients living with a confirmed cancer diagnosis but not yet receiving treatment often describe the interval as a period of acute psychological distress, compounding the medical concern that comes with a longer wait.

Disparities in how the lengthening delays are distributed across different patient populations are noted as an area requiring further research. Prior healthcare-access research has consistently found that structural barriers — geography, insurance status, and access to specialist referral networks among them — tend to widen during periods of system strain, and the study's authors say understanding whether that pattern holds for treatment-timing delays specifically is an important next step.

Health system administrators and policymakers reviewing findings like these have generally focused on two broad levers: expanding oncology workforce capacity through training and recruitment, and streamlining the diagnostic-to-treatment pathway itself so that necessary steps happen in parallel rather than in sequence wherever clinically safe to do so. Neither lever offers a quick fix, given the multi-year timelines involved in training new specialists or restructuring care pathways.

For now, the study's authors say their findings are intended primarily to establish, with rigorous data, a trend that many oncologists have anecdotally observed in their own practices over recent years — and to make the case that the diagnosis-to-treatment interval deserves the same level of research and policy scrutiny that has historically been directed at treatment itself.